No cell therapy for osteoporosis has received FDA approval. Trials remain investigational. Some European national medicines agencies have not formally approved any such product either; most clinical applications occur in private centres outside strict regulatory frameworks.
Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material. Osteoporosis occurs when remodelling becomes imbalanced, with too much removal and insufficient replacement, leaving a porous, fragile architecture vulnerable to fracture. Placental mesenchymal stem cells have attracted research interest because they can differentiate into osteoblasts, potentially helping restore bone-forming capacity. The mechanism appears to involve both direct cellular replacement of bone-building cells and the release of signalling molecules (cytokines) that shift the remodelling ratio back toward deposition. Early-stage trials are exploring whether cell therapy can slow or partially reverse the density loss that typically accelerates after oestrogen withdrawal in post-menopausal women, though robust efficacy data remain limited.
Am I a candidate? → · Osteoporosis & Bone Health: full overview → · Osteoporosis & Bone Health cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung